This study aimed to assess the impact of the CD34+/CD38- stem cells (SCs) burden in chronic myeloid leukemia (CML) on treatment response and patients’ outcomes. Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.